CNS biotech Myrobalan Therapeutics raises $24M Series A to enter the clinic

2024-01-10

Myrobalan Therapeutics has raised $24 million to enter the clinic with one of its four CNS therapeutic candidates, with the goal of either repairing or restoring functions in patients with neurodegenerative conditions. Neuroscience drug discovery and development has been heating up, with recent high-profile approvals , large startup financings and a pair of multi-billion dollar acquisitions . Medford, MA-based Myrobalan was formed in mid-2021 and is based on findings out of Harvard researcher Zhigang He, and has staff in China as well as the US. It’s a reunion of sorts for CEO Jing Wang, an 18-year biotech veteran who did her PhD in He’s lab in the early aughts. The biotech’s other co-founder is MIT professor Guoping Feng.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构